About Trubion Pharmaceuticals
Trubion Pharmaceuticals is a company based in Seattle (United States) founded in 1999 was acquired by Emergent BioSolutions in August 2010.. Trubion Pharmaceuticals has raised $45.6 million across 3 funding rounds from investors including Emergent BioSolutions, Arch Venture Partners and Frazier Healthcare Partners. Trubion Pharmaceuticals operates in a competitive market with competitors including Alexion, argenx, BigHat, Kodiak Sciences and Visterra, among others.
- Headquarter Seattle, United States
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$45.6 M (USD)
in 3 rounds
-
Latest Funding Round
$10 M (USD), Post-IPO
Sep 03, 2009
-
Investors
Emergent BioSolutions
& 6 more
-
Employee Count
Employee Count
-
Acquired by
Emergent BioSolutions
(Aug 12, 2010)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Trubion Pharmaceuticals
Trubion Pharmaceuticals has successfully raised a total of $45.6M across 3 strategic funding rounds. The most recent funding activity was a Post-IPO round of $10 million completed in September 2009. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Post-IPO — $10.0M
-
First Round
First Round
(01 Nov 2002)
- Investors Count 6
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2009 | Amount | Post-IPO - Trubion Pharmaceuticals | Valuation |
investors |
|
| Jul, 2004 | Amount | Series B - Trubion Pharmaceuticals | Valuation | Prospect Venture Partners , Venrock | |
| Nov, 2002 | Amount | Series A - Trubion Pharmaceuticals | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Trubion Pharmaceuticals
Trubion Pharmaceuticals has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Emergent BioSolutions, Arch Venture Partners and Frazier Healthcare Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made in US life sciences and healthtech firms.
|
Founded Year | Domain | Location | |
|
Venture capital firm focused on tech sectors
|
Founded Year | Domain | Location | |
|
Venture capital firm focused on life science companies
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Trubion Pharmaceuticals
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Trubion Pharmaceuticals
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Trubion Pharmaceuticals Comparisons
Competitors of Trubion Pharmaceuticals
Trubion Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Alexion, argenx, BigHat, Kodiak Sciences and Visterra, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapies for rare and devastating diseases are developed by Alexion.
|
|
| domain | founded_year | HQ Location |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment.
|
|
| domain | founded_year | HQ Location |
Antibody therapies are developed through machine learning and synthetic biology.
|
|
| domain | founded_year | HQ Location |
Therapeutics for retinal diseases are developed by the company.
|
|
| domain | founded_year | HQ Location |
Developer of monoclonal antibodies against infectious diseases
|
|
| domain | founded_year | HQ Location |
Antibody-based drugs for primary myopathies are developed and targeted.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Trubion Pharmaceuticals
Frequently Asked Questions about Trubion Pharmaceuticals
When was Trubion Pharmaceuticals founded?
Trubion Pharmaceuticals was founded in 1999 and raised its 1st funding round 3 years after it was founded.
Where is Trubion Pharmaceuticals located?
Trubion Pharmaceuticals is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
Is Trubion Pharmaceuticals a funded company?
Trubion Pharmaceuticals is a funded company, having raised a total of $45.6M across 3 funding rounds to date. The company's 1st funding round was a Series A of $13.6M, raised on Nov 01, 2002.
What does Trubion Pharmaceuticals do?
Trubion Pharmaceuticals developed antibody-like therapeutics for cancer and autoimmune diseases. Its propeirtary drug assembly platform enabled the development of single-chain protein therapeutics. Its pipeline included a CD-20 directed, Pfizer-partnered therapeutic for autoimmune and inflammatory diseases, and CD-37 targeted, AbbVie partnered candidate for B-cell malignancies. In Aug 2010, the company was acquired by Emergent Biosolutions for 98.6M upfront and upto 38.7M in additional milestone payments.
Who are the top competitors of Trubion Pharmaceuticals?
Trubion Pharmaceuticals's top competitors include argenx, Kodiak Sciences and MacroGenics.
Who are Trubion Pharmaceuticals's investors?
Trubion Pharmaceuticals has 7 investors. Key investors include Emergent BioSolutions, Arch Venture Partners, Frazier Healthcare Partners, Prospect Venture Partners, and Venrock.